March 28, 2014
/PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today provided guidance on topics to be discussed at an upcoming Retail Investor Conference on
Organovo's Chairman and Chief Executive Officer,
, will be presenting on
Thursday, April 10, 2014
, and investors can directly participate in this live, interactive online event. Investors will be invited to ask the company questions in real-time both in the presentation hall as well as the company's "virtual trade booth." Organovo has regularly updated its online presentation at retailinvestorconferences.com, and the company maintains its most recent investor conference for on demand viewing at any time. The most recent version can be viewed now by visiting retailinvestorconferences.com. Because the company maintains 24/7 access to this extensive presentation on its technology and business, it has at times declined to have shorter presentations with a subset of the same information presented to be webcast or recorded, such as the 15 minute short form presentation at the Alliance for Regenerative Medicine investor conference on
, 2014. All information provided at that conference, and more, is found in the current on-demand presentation.
At the upcoming conference on
, Organovo will provide information on several topics, including:
KOL update: guidance on expectations and timelines for key opinion leader (KOL) evaluation of Organovo's 3D Liver tissue;
Cash burn and R&D spending: Review of the company's cash position and expectations of future spending;
Update on progress of bioprinted breast cancer models: New results from Organovo's bioprinted breast cancer models are expected to be released at the upcoming American Association for Cancer Research (AACR) annual meeting, to be held
, CA. Mr. Murphy will review the results on the live investor conference on
Advantages of NovoGen 3D Bioprinting versus currently available methods and technologies: Organovo will cover the advantages of its NovoGen 3D Bioprinting to achieve breakthroughs in the creation of living tissue, including up to date data from its 3D Liver product. Based on the performance of the liver to date, which will be reviewed at the conference, the company believes its human liver model currently in development has the opportunity to redefine the category of in vitro assays as being fully human; multicellular; three dimensional in size, shape, and substance; and consistent in form and function with a native tissue sample. It also believes this set of attributes is unique and umatched by current products and technologies, none of which use any form of bioprinting today.